

AN INVESTIGATION ON THE RELATIONSHIP BETWEEN VANADIUM AND ANTIOXIDATIVE ENZYME SYSTEM IN RATS

Ahmet AYDIN*, Ahmet SAYAL, Savaş SAYIN, Onur ERDEM

Gülhane Military Medical Academy, Department of Pharmaceutical Toxicology
Etlik -Ankara , TURKEY

Abstract

The aim of the study is to investigate the relationship between free oxygen radicals and vanadium in vanadium cytotoxicity. For this purpose erythrocyte copper zinc superoxide dismutase (CuZn-SOD) erythrocyte and plasma selenium dependent glutathione peroxidase (SeGSH-Px) enzyme activities, erythrocyte thiobarbituric acid reactive substances (TBARS) levels, erythrocyte and plasma vanadium levels were measured in Sprague Dawley rats fed with 0.15mgV/ml in tap water for the period of 15 days. And also water, food consumption and weight loss were followed during the test. Control rats were fed with normal tap water. Erythrocyte CuZn-SOD (175.4±61.40 U/ml) and plasma SeGSH-Px (0.50±0.05 U/ml) activities were significantly lower than that of control group (519.90±67.84 and 0.63±0.09 U/ml respectively) ($p<0.001$ and $p<0.05$ respectively). On the other hand erythrocyte SeGSH-Px activities (21.20±2.60 U/ml) were not different from control group (22.85±4.50 U/ml). There was significant difference between erythrocyte TBARS levels of test group and control group (7.91±3.00 nmol/ml, 6.03±3.00 nmol/ml respectively). Plasma vanadium levels (18±3.92 ng/ml) and erythrocyte vanadium levels (140.50±10.33 ng/ml) of test group were significantly higher than that of control group (3.22±0.83 ng/ml and 16.11±2.85 ng/ml respectively) ($p<0.001$). At the end of the test the body weight of test animals (133±6.25 g) were significantly lower than that of control animals (180.80±4.25 g) ($p<0.001$). As a result, it has been concluded that free radical production could be responsible for the vanadium cytotoxicity.

Key words: Vanadium, Lipid peroxidation, Antioxidant enzymes

Sıçanlarda Vanadyum ve Antioksidan Sistem Arasındaki İlişkinin Araştırılması

Bu çalışmanın amacı vanadyum (V) sitotoksitesinde serbest oksijen radikalleri ve V arasındaki ilişkiyi incelemektir. Bu amaçla 15 gün süreyle mililitrede 0.15 mg V içeren içme sularıyla beslenen Sprague Dawley cinsi dişi sıçanlarda eritrosit bakır-çinko süperoksit dismutaz (CuZn-SOD), eritrosit tiobarbitürik asit reaktif ürünleri (TBARS), eritrosit ve plazma V seviyeleri ölçüldü. Aynı zamanda yiyecek ve su tüketimleriyle kilo kayıpları da deney boyunca takip edildi. Kontrol grubu sıçanlara normal çeşme suyu verildi. Eritrosit CuZn-SOD (175.4±61.40 U/ml) ve plazma SeGSH-Px (0.50±0.05 U/ml) aktiviteleri kontrol grubundaki değerlerden (sırasıyla 519.90±67.84 and 0.63±0.09 U/ml) anlamlı olarak daha düşüktü (sırasıyla $p<0.001$ and $p<0.05$). Eritrosit SeGSH-Px aktiviteleri (21.20±2.60 U/ml) kontrol grubundan (22.85±4.50 U/ml) farklı değildi. Deney ve kontrol gruplarının eritrosit TBARS düzeyleri (sırasıyla 7.91±3.00 nmol/ml, 6.03±3.00 nmol/ml) arasında anlamlı bir fark tespit edildi. Deney gruplarının plazma V düzeyleri (18±3.92 ng/ml) ve eritrosit V düzeyleri (140.50±10.33 ng/ml) kontrol grubundaki değerlerden (3.22±0.83 ng/ml and 16.11±2.85 ng/ml) daha yüksekti ($p<0.001$). Deney grubu sıçanların deney sonundaki vücut ağırlıkları (133±6.25 g) kontrol grubu sıçanların ağırlıklarından (180.80±4.25 g) anlamlı olarak düşük bulundu ($p<0.001$). Sonuç olarak serbest radikal üretiminin V sitotoksitesinden sorumlu olabileceği kanısına varılmıştır.

Anahtar Kelimeler: Vanadyum, Lipid peroksidasyonu, Antioksidan enzimler.

*Corresponding author: Tel.: +90 312 3046071, Fax: +90 312 3046091
e-mail: ahmetaydin30@hotmail.com

INTRODUCTION

Vanadium is widely recognized as a potentially toxic environmental pollutant (1,2). Due to fossil fuel burning, as much as 66 000 tons of vanadium is released into the atmosphere and further redistributed in the environment each year. Although vanadium is known to be essential for a number of species, its role as a micronutrient in humans has yet to be established (3). Vanadium enters the organism by inhalation, the gastrointestinal tract and the skin. Once absorbed, vanadate is reduced to vanadyl by the glutathione of erythrocytes or by ascorbic acid and other reducing substances in plasma and its transported by albumin and transferrin (4). Vanadium is especially stored in certain organs, mainly in bone, kidney and liver (5).

There are now increasing evidence that vanadium can also be toxic to living system (6,7). Epidemiological studies have shown a correlation between vanadium exposure and the incidence of lung cancer in human (8-11). While the mechanisms of vanadium's toxicity and carcinogenicity remain to be investigated, it has been reported that this metal is able to regulate growth-factor-mediated signal transduction pathways, promote cell transformation, exert inhibitory effect on certain enzymatic systems, and decrease cell adhesion (12-14). Vanadium compounds were also reported to cause direct DNA damage (15).

There are many data that in vitro vanadium induces lipid peroxidation in purified and partially peroxidized fatty acids, phospholipids and lipid tissue extracts (16-18), as well as in a great variety of biological systems: mitochondria (19), microsomes from liver, brain and human placenta (18-21), erythrocytes (22), isolated liver cells (23) and mouse and rat tissues (24). Some of the authors suggest that lipid peroxidation underlies vanadium toxicity (21-25).

It has long been known that vanadium can stimulate oxidation of fatty acid lipids (17). Recent reports have described vanadium-dependent lipid peroxidation in human erythrocytes (22) and in animals treated acutely and chronically with vanadium (26). In all of these reports, the initial events are unclear, but strong evidence suggests possible free radical involvement. Lipid peroxidation, a process known to involve active oxygen species, can lead to pathological effects on biological membranes including permeability changes and possible cell lysis (27).

Little is also known about the in vivo effects of vanadate on antioxidant enzymes. Increased glutathione peroxidase and glutathione reductase activities in lungs (28) as well as unchanged CuZn-SOD and Mn-SOD activities in liver have been reported (29).

In this study we aimed to investigate the relationship between free oxygen radicals and vanadium in vanadium cytotoxicity. For this purpose erythrocyte CuZn-SOD activity, erythrocyte and plasma Se-GSH-Px enzyme activities, erythrocyte TBARS, erythrocyte and plasma vanadium levels were measured in Sprague Dawley Rats.

EXPERIMENTAL

Materials

Twenty Sprague Dawley rats were used in this study. Animals were divided equally into two groups of ten as control and exposed. Control group received water to drink. Animals of exposed group were given solely an aqueous solution of ammonium meta vanadate (AMV) 0.15 mg/ml/V

for fifteen days. Food and fluid intakes were measured daily and body weight were monitored weekly during the test. Blood samples were taken. Whole blood was separated into plasma and erythrocyte fractions by centrifugation (4000g, 6min) at 4°C. Immediately after separation, the erythrocyte fractions were washed three times with an isotonic saline. Then, erythrocytes were lysed with cold distilled water (1:4); stored in a refrigerator at 4°C for 15 min and the erythrocyte membranes were removed. Plasma samples and erythrocyte lysates were stored at -70°C until assays.

All reagents used in this study were of analytical grade and obtained from Sigma Chemical Co. (St. Louis, MO, USA) and Merck (Darmstadt, Germany).

Methods

CuZn-SOD activity measurement

CuZn-SOD activity in erythrocyte lysate was measured by the method described in our previous study (30). Briefly, each hemolysate was diluted 1:400 with 10mM phosphate buffer, pH 7.00. 25 µL of diluted hemolysate was mixed with 850 µL of substrate solution containing 0.05 mmol/L xanthine sodium and 0.025 mmol/L 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride (INT) in a buffer solution containing 50mmol/L CAPS and 0.94mmol/L EDTA pH 10.2. Then, 125 µL of xanthine oxidase (80U/L) was added to the mixture and absorbance increase was followed at 505 nm for 3 min against air. 25 µL of phosphate buffer or 25 µL of various standard concentrations in place of sample were used as blank or standard determinations. CuZn-SOD activity was expressed in U/ml.

SeGSH-Px activity measurement

SeGSH-Px activities in both erythrocyte lysate and plasma samples were measured by the method described in our previous study (30). The reaction mixture was 50mmol/L tris buffer, pH 7.6 containing 1mmol/L of Na₂EDTA, 2 mmol/L of reduced glutathione (GSH), 0.2 mmol/L of NADPH, 4 mmol/L of sodium azide and 1000U of glutathione reductase (GR) 50 µL of plasma and 950 µL of reaction mixture, or 20 µL of erythrocyte lysate and 980 µL of reaction mixture were mixed and incubated for 5 min. at 37°C. Then the reaction was initiated with 8 mmol/L H₂O₂ and the decrease in NADPH absorbance was followed at 340nm for 3 min. Enzyme activities were reported as U/ml in erythrocyte lysate and plasma.

TBARS level measurement

Erythrocyte TBARS levels were determined in erythrocyte lysates obtained after centrifugation and in accordance with the method described in our previous study (30). After the reaction of thiobarbituric acid with malondialdehyde, the reaction product was measured spectrophotometrically. Tetramethoxy propane solution was used as standard. TBARS level of erythrocyte were expressed as nmol/L .

Vanadium level measurement

Determination of vanadium was performed on a Varian 30/40 atomic absorption spectrophotometer, a varian GTA 96 graphite tube atomizer and a Varian DS-15 data station. The graphite furnace was purged with pre-purified argon gas during operation. Gas ‘stop condition’ was used only during the atomization cycle. A varian autosampler was used to inject 10µl aliquots of sample solution. The standard solutions of Vanadium were prepared with nitric acid (Merck) at various concentrations such as 25, 50, 75, and 100 ng per ml. All standart solutions were prepared daily. Plasma and erythrocyte samples were diluted with triton X-100 (Sigma). Pyrolytically coated graphite tubes (i.d. 5.8 mm-o.d.80 mm and length 28.0 mm) were used. The mixtures were transferred to the autosampler of the graphite furnace and the results were taken from the printer. The instrument parameters were as follows:

RESULTS

The AMV exposed rats which received, as sole drinking liquid, the aqueous solution of AMV (0.15mg V/ml) for 15 days, we observed the typical symptoms of vanadium intoxication: diminished food and water consumption, supression of body weight increment (Table 1). The volume of liquid and the amount of food taken up by the vanadate-treated rats were decreased by 30% and 33% respectively low as compared to their controls. The present results in agreement with previous studies suggest that the supression of the body weight increment in animals intoxicated with AMV, is largely due to the decreased food and water uptake (31,32).

Table 1. The effect of amonium metavanadate (AMV) on food and fluid intake and body weight in tested rats.

Group of animals	Number of animals examined	Initial weight of animals (g)	Weight of animals after 15 days	Food intake g/rat/24h	Fluid intake ml/rat/24h
Control	10	144.55±5.65	180.80±4.25	18.30±0.75	29.80±1.20
AMV	10	149.70±5.34	133.00±6.25*	12.20±0.65*	21.00±1.80*

The results are given as mean values ± SEM

*p<0.001, significantly different from control group

Table 2 shows antioxidant enzyme activities of control and AMV treatment rats. Erythrocyte CuZn-SOD and plasma SeGSH-Px activities were significantly lower than that of control group (p<0.001 and p<0.05 respectively). On the other hand erythrocyte SeGSH-Px activities were not different from control group. There was no significant difference between TBARS levels of test and control group. Plasma and erythrocyte vanadium levels of test group were significantly higher than that of control group (p<0.001).

DISCUSSION AND CONCLUSION

In the investigations described here the suppressed body weight increment appears to be due to a decrease in food consumption, rather than to a decrease in food efficiency. The smaller body weight increment recorded at present and previous studies (31,32).

Table 2. The comparison of antioxidant enzyme activities and malondialdehyde levels in control and AMV treatment rats.

	Control	AMV	p value
Erythrocyte CuZn-SOD (U/ml)	519.90±67.84	175.40±61.40	p<0.001
Plasma SeGSH-Px (U/ml)	0.63±0.09	0.50±0.05	p<0.05
Erythrocyte SeGSH-Px (U/ml)	22.85±4.50	21.20±2.60	p>0.05
Erythrocyte MDA (nmol/ml)	6.03±3.00	7.91±3.00	p<0.05
Plasma vanadium (ng/ml)	3.22±0.83	18.00±3.92	p<0.001
Erythrocyte vanadium (ng/ml)	16.11±2.85	140.50±10.33	p<0.001

The results are given as mean values ± SEM

Also we suggested that this anorexigenic effect of vanadium is due to a stimulation of glucose uptake by the central nervous system (33,34).

Free oxygen radicals are the molecules which contain unpaired electrons. They are also called as 'oxidant molecules' or 'reactive oxygen species'. Reactive oxygen metabolites are constant products of normal aerobic cell metabolism. Healthy organisms are protected by various defense mechanisms against free oxygen radicals which are ceaselessly generated. These oxidants are degraded by enzyme systems such as superoxide dismutase (SOD), catalase, glutathione peroxidase (GSH-Px) and antioxidant such as ceruloplasmin, transferrin, reduced glutathione (GSH), methionine, vitamin E and C. MDA is the product of lipid peroxidation which occurs as a result of free radical injury and its formation is accelerated by oxidative stress. The amount of MDA produced, as measured by the thiobarbituric acid (TBA) assay, has been shown to be a true indicator of endogenous lipid peroxidation, Vanadium as sodium orthovanadate induces an increase in lipid peroxidation in the kidneys after a single subcutaneous or intraperitoneal injection to rats or mice. The rate of MDA formation increased more than 100% 1 hour after 10 weeks in kidney homogenates of these animals but not in other tissues (26).

In this study, erythrocyte TBARS levels were found at higher concentration with vanadium. There was significant difference between TBARS levels of AMV and control group. The effect of vanadium treatment on TBARS levels is similar to previous reports. Donaldson and LaBella reported that rat and mouse tissues incubated with sodium metavanadate (NaNO₃) exhibited high indices of lipid peroxidative damage, as measured by tissue MDA levels compared to control

tissues (24). Similarly, Elfant and Keen reported that pregnant and lactating rats fed with diets containing 75µg NaVO₃/g for 43 days showed high MDA levels both in whole liver homogenate and mitochondrial fragments compared to controls (29). These observations show that vanadium can directly or indirectly induce oxidative changes to erythrocytes and tissues.

Haider and El-Fakhri reported that, intraperitoneal sodium metavanadate (2.5, 3.5 or 5.0mg/kg) administration to rats, for 7, 3 or 2 consecutive days enhanced lipid peroxidation in various rat brain fractions. However, an administration of alpha-tocopherol in combination with sodium metavanadate decreased the vanadium-stimulated lipid peroxidation (35) .

Lipid peroxidation was increased in liver and kidney rats received an aqueous solution of AMV (0.15mg/V/ml), but no increase in the erythrocytes was observed. However CuZn-SOD and SeGSH-Px enzyme activities in blood remained the same in contrast with our previous study (31).

It can be concluded with these results that free radical production can be responsible for vanadium toxicity. Heider and El-Fakhri demonstrated that antioxidant therapy prevented the cytotoxicity of vanadium (35). As our knowledge vanadium can reduce blood glucose levels in some previous studies (36,37). At that point if vanadium is used for antidiabetic activities, the antioxidant intake can be offer during the vanadium therapy.

REFERENCES

1. **Zychlinski L, Byczkowski JZ.**, “Inhibitory effects of vanadium pentoxide on respiration of rat liver mitochondria” *Arch. Environ. Contam. Toxicol.*, 19, 138-142, **1990**.
2. **Zychlinski L, Byczkowski JZ, Kulkami AP.**, “Toxic effects of long term intratracheal administration of vanadium pentoxide in rats” *Arch. Environ. Contam. Toxicol.*, 20, 295-298, **1991**.
3. **Nriagu JO, Pacyna JM.**, “Quantitative assessment of worldwide contamination of air, water and soils by trace elements” *Nature*, 333, 134-139, **1988**.
4. **Degani H, Gochin M, Karlsh SJD, Shechter Y.**, “Electron paramagnetic studies and insulin-like effects of vanadium in rat adipocytes” *Biochemistry*, 20, 5795-5799, **1981**.
5. **Etcheverry SB, Cortizo AM.**, “Bioactivity of vanadium compounds on cells in culture. In: Nriagu, JO (Ed), *Vanadium in the environment*” Wiley, New York, 359-394, **1998**.
6. **Domingo JL.**, “Vanadium: a review of the reproductive and developmental toxicity” *Reprod. Toxicol.*, 10, 175-182, **1996**.
7. **Sabbioni E, Pozzi G, Devos S, Pintar A, Casella L, Fischbach M.**, “The intensity of vanadium (V)-induced biotoxicity and morphological transformation in BALB/3T3 cells independent on glutathione-mediated bioreduction to vanadium (IV)” *Carcinogenesis* 14, 2565-2568, **1993**.
8. **Stock P.**, “On the relations between atmospheric pollution in urban and rural localities and mortality from cancer, bronchitis, pneumonia, with particular reference to 3,4-benzopyrene, beryllium, molybdenum, vanadium and arsenic” *Br. J. Cancer.*, 14, 397-418, **1960**.

9. **Hickey RJ, Schoff EP, Clelland P.**, "Relationship between air pollution and certain chronic disease death rates" *Arch. Environ. Health.* 15, 728-738, **1967.**
10. **Zhong BZ, Gu ZW, Wallace WE, Whong WZ, Ong T.**, "Genotoxicity of vanadium pentoxide in chinese hamster V79 cells" *Mutat. Res.*, 321, 35-42, **1984.**
11. **Leonard A, Gerber GB.**, "Mutagenicity, carcinogenicity and teratogenicity of vanadium compounds" *Mutat. Res.*, 317, 81-88, **1994.**
12. **Faure R, Vincent M, Dufour M, Shaver A, Posner BI.**, "Arrest at the G₂/M transition of the cell cycle by protein tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line" *J. Cell Biochem.*, 58, 389-401, **1995.**
13. **Strasberg RM, Rieber M.**, "Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation" *Biochem. Biophys. Res. Commun.*, 216, 422-427, **1995.**
14. **Wang H, Xie Z, Scott RE.**, "Induction of AP-1 activity associated with c-Jun and JunB is required for mitogenesis induced by insulin and vanadate in SV40-transformed 3T3T cells" *Mol. Cell. Biochem.*, 168, 21-30, **1995.**
15. **Shi X, Jiang H, Mao Y, Ye J, Saffiotti U.**, "Vanadium(IV)-mediated free radical generation and related 2'-deoxyguanosine hydroxylation and DNA damage" *Toxicology*, 106, 27-38, **1996.**
16. **Inouye B, Morita K, Ishida T, Ogata M.**, "Cooperative effect of sulfite and vanadium compounds on lipid peroxidation" *Toxic. Appl. Pharmac.*, 53, 101-107, **1980.**
17. **Keller RJ, Sharma RP, Grover TA, Piette LH.**, "Vanadium and lipid peroxidation: evidence for involvement of vanadyl and hydroxyl radical" *Archs. Biochem. Biophys.*, 265, 524-533, **1988.**
18. **Liochev S, Ivancheva E, Russanov E.**, "Vanadyl and Vanadate-induced lipid peroxidation in mitochondria and in phosphatidylcholine suspension" *Free Rad. Res. Commun.*, 4, 317-325, **1988.**
19. **Svoboda P, Teisinger S, Vyskocil T.**, "Vanadyl (VO²⁺)-induced lipid peroxidation in the brain microsomal fraction is not related to VO²⁺ inhibition of Na,K-ATP-ase" *Biochem. Pharmac.*, 33, 2493-2497, **1984.**
20. **Byczkowski JZ, Wan B, Kulkarni AP.**, "Vanadium mediated lipid peroxidation in microsomes from human term placenta" *Bull. Environ. Contam. Toxic.*, 41, 696-703, **1988.**
21. **Byczkowski JZ, Kulkarni AP.**, "Vanadium redox cycling, lipid peroxidation and co-oxigenation of benzo(a)pyrene-7,8-dihydrodiol" *Biochem. Biophys. Acta.*, 1125, 134-141, **1992.**
22. **Heller KB, Jahn B, Deuticke B.**, "Peroxidative membrane damage in human erythrocytes induced by a concerted action of iodoacetate, vanadate and ferricyanide" *Biochim. Biophys. Acta.*, 901, 67-77, **1987.**
23. **Younes M, Albrecht M, Siegers CP.**, "Lipid peroxidation and lysosomal enzyme release induced by vanadate in vitro" *Commun. Chem. Pathol. Pharmac.*, 43, 487-495, **1984.**

24. **Donaldson J, LaBella FS.**, “Prooxidant properties of vanadate in vitro on catecholamines and on lipid peroxidation in mouse and rat tissues” *J. Toxic. Envir. Hlth.*, 12, 109-113, **1983**.
25. **Younes M, Strubelt O.**, “Vanadate-induced toxicity towards isolated perfused rat livers: the role of lipid peroxidation” *Toxicology*, 66, 63-74, **1991**.
26. **Donaldson J, Memming R, LaBella F.**, “Vanadium exposure enhances lipid peroxidation in the kidney of rats and mice” *Can. J. Physiol. Pharmac.*, 63, 196-199, **1985**.
27. **Kappus H.**, “Oxidative Stress” Academic Press., London, 273-310, **1985**.
28. **Wennig R, Kirsch N.**, “Vanadium. In Handbook on toxicity of inorganic compounds (Edited by Seiler HG, Siegel H, Siegel A.)” Dekker, New York, 749-765, **1988**.
29. **Elfant M, Keen CL.**, “Sodium vanadate toxicity in adult and developing rats. Role of peroxidative damage” *Biol. Trace. Elem. Res.* 14, 193-207, **1987**.
30. **Aydın A, Orhan H, Sayal A, Özata M, Şahin G, Işımer A.**, “Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control” *Clin. Biochem.* 34, 65-70, **2001**.
31. **Russanov E, Zaporowska H, Ivancheva E, Kirkova M, Konstantinova S.**, “Lipid peroxidation and antioxidant enzymes in vanadate treated rats” *Comp. Biochem. Physiol.*, 107C, 514-521, **1994**.
32. **Zaprowska H, Waisilewski W.**, “Significance of reduced food and water consumption in rats intoxicated with vanadium” *Comp. Biochem.*, 99C, 349-352, **1991**.
33. **Brichard SM, Lederer S, Henquin JC.**, “Vanadium compounds as a new class of therapeutical agents for treatment of diabetes mellitus” *Diabet & Mellitus*, 17, 435-440, **1991**.
34. **Meyerovitch J, Shechter Y, Amir S.**, “Vanadate stimulates in vivo glucose uptake in brain and arrats food intake and body weight gain in rats” *Physiol. Behav.*, 45, 1113-1116, **1989**.
35. **Heider SS, El-Fakhri M.**, “Action of alpha-tocopherol on vanadium stimulated lipid peroxidation in rat brain” *Neurotoxicology*, 12, 79-86, **1991**.
36. **Brichard SM, Henquin JC.**, “The role of vanadium in the menagement of diabetes” *Trends Pharmacol. Sci.*, 16, 265-270, **1995**.
37. **Sekar N, Li J, Shechter Y.**, “Vanadium salts as insulin substitutes: mechanism of action, a scientific and therapeutic tool in diabetes mellitus research” *Crit Rev. Biochem. Mol. Biol.*, 31, 339-59, **1996**.

received: 17.03.2005
accepted: 06.05.2005